Is Ocugen Headed for a Breakdown?

This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEC3B0CQ_M.jpg

The company has in-licensed Covaxin, a whole-virion vaccine for Covid-19 that may have advantages over current vaccines in use today, but the earliest it will be approved is in the second quarter of 2023.

OCGN has a very high current ratio of 12.0 and a debt-to-equity ratio of 0.1. The company has had negative recent earnings and estimates for more negative earnings until 2022.

Continue reading on StockNews

Add Comment